IR of thrombosis according to different doses of L-Asparaginase
. | Populations . | N . | Events . | IR, % (95% CI) . | Heterogeneity across groups, P . |
|---|---|---|---|---|---|
| Total dose | .46 | ||||
| 20 000 to 59 000 U/m2 | 7 | 202 | 8 | 3.9 (1.8-7.5) | |
| 60 000 to 79 000 U/m2 | 2 | 760 | 41 | 5.4 (3.9-7.2) | |
| 80 000 U/m2 or higher | 8 | 318 | 12 | 3.8 (2.0-6.4) | |
| Daily dose | < .001 | ||||
| 6 000 U/m2 or less | 7 | 476 | 38 | 8.0 (5.7-10.8) | |
| 10 000 U/m2 or higher | 10 | 804 | 23 | 2.9 (1.9-4.2) | |
| Total days | < .001 | ||||
| Fewer than 9 days | 14 | 945 | 29 | 3.1 (2.1-4.3) | |
| 9 or more days | 3 | 335 | 32 | 9.6 (6.6-13.3) | |
| Interaction between ASP daily dose and length of therapy | < .001 | ||||
| Fewer than 9 days, 6 000 U/m2 or less | 4 | 141 | 6 | 4.4 (1.7-8.8) | |
| Fewer than 9 days, 10 000 U/m2 or higher | 10 | 804 | 23 | 2.9 (1.8-4.2) | |
| 9 or more days, 6 000 U/m2 or less | 3 | 335 | 32 | 9.6 (6.6-13.3) | |
| 9 or more days, 10 000 U/m2 or higher | 0 | 0 | 0 | NA |
. | Populations . | N . | Events . | IR, % (95% CI) . | Heterogeneity across groups, P . |
|---|---|---|---|---|---|
| Total dose | .46 | ||||
| 20 000 to 59 000 U/m2 | 7 | 202 | 8 | 3.9 (1.8-7.5) | |
| 60 000 to 79 000 U/m2 | 2 | 760 | 41 | 5.4 (3.9-7.2) | |
| 80 000 U/m2 or higher | 8 | 318 | 12 | 3.8 (2.0-6.4) | |
| Daily dose | < .001 | ||||
| 6 000 U/m2 or less | 7 | 476 | 38 | 8.0 (5.7-10.8) | |
| 10 000 U/m2 or higher | 10 | 804 | 23 | 2.9 (1.9-4.2) | |
| Total days | < .001 | ||||
| Fewer than 9 days | 14 | 945 | 29 | 3.1 (2.1-4.3) | |
| 9 or more days | 3 | 335 | 32 | 9.6 (6.6-13.3) | |
| Interaction between ASP daily dose and length of therapy | < .001 | ||||
| Fewer than 9 days, 6 000 U/m2 or less | 4 | 141 | 6 | 4.4 (1.7-8.8) | |
| Fewer than 9 days, 10 000 U/m2 or higher | 10 | 804 | 23 | 2.9 (1.8-4.2) | |
| 9 or more days, 6 000 U/m2 or less | 3 | 335 | 32 | 9.6 (6.6-13.3) | |
| 9 or more days, 10 000 U/m2 or higher | 0 | 0 | 0 | NA |